Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.05 | N/A | N/A | N/A |
2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-09-16 | Ascendiant Capital | Upgrade | Buy | |
2019-12-17 | Maxim Group | Upgrade | Hold | Buy |
2018-01-25 | Maxim Group | Upgrade | Buy | |
2013-10-06 | Sidoti & Co. | Downgrade | Buy | Neutral |
2013-04-14 | Sidoti & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-03-08 | CHEN SHU-CHIH | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2013-05-14 | CROSS ALEXANDER DENNIS | Director | 0.00 | Purchase |
2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
2017-11-14 | GUSE KYLE | General Counsel | 10.00K | Purchase |
2016-03-08 | QUAY STEVEN C | Chief Executive Officer | 0.00 | Purchase |
2017-04-16 | REMMEL H LAWRENCE | Director | 3.13K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 5.68M | 7.15M | 4.51% |
2023-06-29 | Blackrock Inc. | 2.90M | 3.65M | 2.30% |
2023-06-29 | Laurion Capital Management, LP | 2.23M | 2.80M | 1.77% |
2023-06-29 | Geode Capital Management, LLC | 1.11M | 1.40M | 0.88% |
2023-06-29 | Renaissance Technologies, LLC | 1.07M | 1.35M | 0.85% |
2023-06-29 | State Street Corporation | 436.27K | 549.70K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.78M | 4.76M | 3.00% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.66M | 2.10M | 1.32% |
2023-05-30 | Fidelity Extended Market Index Fund | 659.95K | 613.75K | 0.52% |
2023-05-30 | BlackRock Advantage Small Cap Core Fund | 340.50K | 316.67K | 0.27% |
2023-05-30 | Fidelity Total Market Index Fund | 182.91K | 170.11K | 0.15% |
2023-05-30 | Fidelity Series Total Market Index Fund | 142.17K | 132.22K | 0.11% |
Split | Date |
---|---|
1 : 12 | 2018-04-20 |
1 : 15 | 2016-08-26 |
-
This could get ugly....
-
The reason Crypto is running so hard is retail investors are seeing the massive manipulation of the stock market going unchecked, and moving to Crypto. Naked Shorting is out of control and the SEC is doing nothing to address it. Biden isn’t a stock market guy, so he doesn’t understand it and therefore it’s not a priority to him. Until they get a hold on this manipulation of the markets, it’s going to suffer.
-
Y’all got to stop get frenzied up by peoples wild speculations about what is or isn’t going to happen at this Conference. Chances are the stock price is going to dip a good bit, guaranteed so if no news is released. If you were long before you should be long still unless negative news is released. There are meetings scheduled with investing firms and I doubt Quay is coming to give them a presentation without having something new.
Holding 24k shares
Will be swinging 14k, holding 10k in reserve. -
Outside of its current investors, nobody in public is aware of them developing a Covid Nasal Spray. You’d think the CRO would have someone in the PR dept putting that info out there daily on social media. Doesn’t even have to be real news, it could be “excited at the progress we are making!” It’s all about generating awareness, excitement and optimism. It makes people want to invest in your company.
-
Just inept management. People always wonder why Tesla is valued at what it is, it’s because Elon keeps them in the media. Always doing something, tweeting something, promoting it in some way. It might be just to congratulate James the custodian on doing a great job. But it’s something to keep the company in the media. And it’s literally free to do. You’d think CEOs would follow that blueprint. But most of them are oblivious.
-
Big dip...
-
Do you realize how stupid you sound with the “paper” and “Diamond” hands?
-
Better hope they come with something in the Conference. Otherwise we gonna see 1.70s range again
-
Us “Penny flippers” made $1600 today on this stock, adding a free 500 shares and pocketing the rest, while you’re still praying it goes to $3 so your 300 shares will make you $100.
Btw, don’t get mad when it drops to 2.33 here in a bit, dulling your enthusiasm. If you had the brains to swing half your position every day, you’d have already made some profit.
-
$ATOS
Time for shorts to cover -
Nice lil volume spike
-
Has nothing to do with people selling. Just shows that you know absolutely nothing on how the process actually works.
-
Lol, management should be putting out PR daily just mentioning the Conference. It’s literally free and takes 30 seconds to send a tweet, an email, anything on social media. Lol they are clueless. This is why this stock underperforms even with all the potential it has. Extremely poor management from its PR department.
-
$ATOS
Almost time to go up! -
Now you see why we swing trade half of our ATOS shares daily. Only way to make money on this stock.
-
Rule of thumb: when everyone on the board assures you it’s going up, sell and wait for the dip. 99% of people on here have no clue what they are doing.
-
Good old Seger!!
-
Sold 10k at 2.45
Holding 14k on sideWill renter at 2.25 for 12k shares.
This could go either way this week. SHORTS took a large position this morning. They are expecting the sell off that normally happens leading up to the Conference. This could see 2.10 range with nothing new coming out from Dr Quay. Or could rocket up with any developments. Cover yourself on both ends.
-
SHORTS are loading up on this because they are expecting a selloff leading up to the Conference
-
2.25 incoming
-
Atos: contract to reinforce a supercomputer in Sweden
news.google.com • -
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
globenewswire.com • -
3 Dirt-Cheap Drug Developers With Blockbuster Potential
investorplace.com • -
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
investorplace.com • -
Atossa Therapeutics names Heather Rees as CFO
proactiveinvestors.com • -
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
globenewswire.com • -
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
globenewswire.com • -
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
investorplace.com • -
Atossa to Present at the Sidoti Small-Cap Investor Conference
globenewswire.com •